Nature Communications (Jan 2022)

Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2

  • Lamiaa El-Shennawy,
  • Andrew D. Hoffmann,
  • Nurmaa Khund Dashzeveg,
  • Kathleen M. McAndrews,
  • Paul J. Mehl,
  • Daphne Cornish,
  • Zihao Yu,
  • Valerie L. Tokars,
  • Vlad Nicolaescu,
  • Anastasia Tomatsidou,
  • Chengsheng Mao,
  • Christopher J. Felicelli,
  • Chia-Feng Tsai,
  • Carolina Ostiguin,
  • Yuzhi Jia,
  • Lin Li,
  • Kevin Furlong,
  • Jan Wysocki,
  • Xin Luo,
  • Carolina F. Ruivo,
  • Daniel Batlle,
  • Thomas J. Hope,
  • Yang Shen,
  • Young Kwang Chae,
  • Hui Zhang,
  • Valerie S. LeBleu,
  • Tujin Shi,
  • Suchitra Swaminathan,
  • Yuan Luo,
  • Dominique Missiakas,
  • Glenn C. Randall,
  • Alexis R. Demonbreun,
  • Michael G. Ison,
  • Raghu Kalluri,
  • Deyu Fang,
  • Huiping Liu

DOI
https://doi.org/10.1038/s41467-021-27893-2
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 14

Abstract

Read online

El-Shennawy et al. report that ACE2+ circulating extracellular vesicles (evACE2) are associated with COVID-19 severity and that evACE2 inhibits the infection of SARS-CoV-2 variants of concern at a higher efficacy than soluble ACE2.